Another single-center, single-arm, phase I clinical trial (NCT03126864) also assessed the efficacy and safety of CD33 CAR-T therapy in 10 patients with R/R AML, but CAR-T cells were only successfully infused in 3 patients and they all died due to disease progression (66). This evidence concerns the gene CD33 and acute myeloid leukemia.